Neurocrine Biosciences | NBIX - Cash And Equivalent


Neurocrine Biosciences reported $332.4M in Cash and Equivalent for its fiscal quarter ending in June of 2026.





Cash And Equivalent Change Date
AbbVie USD 6.57B 2.82B Jun/2026
Acadia Pharmaceuticals USD 956.47M 105.02M Jun/2026
Agios Pharmaceuticals USD 99.65M 13.95M Jun/2026
ALKERMES USD 511.53M 159.98M Jun/2026
Alnylam Pharmaceuticals USD 1.71B 2.46M Jun/2026
Amgen USD 13.99B 1.95B Jun/2026
Biogen USD 1.28B 2.1B Jun/2026
BioMarin Pharmaceutical USD 874M 1.35B Jun/2026
Cytokinetics USD 255.27M 125.43M Jun/2026
Enanta Pharmaceuticals USD 37.44M 5.14M Dec/2025
Exelixis USD 226.15M 256.34M Mar/2026
Gilead Sciences USD 7.63B 64M Mar/2026
Halozyme Therapeutics USD 163.14M 146.61M Jun/2026
Incyte USD 3.98B 33.45M Jun/2026
Ionis Pharmaceuticals USD 350.06M 1.57B Jun/2026
Nektar Therapeutics USD 149.58M 134.46M Mar/2026
Neurocrine Biosciences USD 332.4M 65.9M Jun/2026
Pfizer USD 976M 727M Jun/2026
Prothena USD 288.19M 41.27M Jun/2026
Regeneron Pharmaceuticals USD 2.46B 506.8M Jun/2026
Repligen USD 606.78M 24.13M Jun/2026
Rigel Pharmaceuticals USD 48.53M 4.87M Sep/2025
Sarepta Therapeutics USD 571.15M 106.7M Jun/2026
Teva Pharmaceutical Industries USD 3.74B 185M Mar/2026
Ultragenyx Pharmaceutical USD 125M 50M Jun/2026
Vertex Pharmaceuticals USD 7.85B 605.7M Jun/2026